Capricor Therapeutics (CAPR) stock

Market cap $486M

$8.94

-5.60%

Market closed. Prices as of Thursday's close.

Quality Score

-3

Poor

In its industry

#182of 276

Biotech

Checks firing

2of 14

Choppy

From 52-week high

-77.9%

Below the 200-day

NextNov 22, 2026 · In 51 days“– New PDUFA target action date of November 22, 2026…”FDA decision date · 8-K, Aug 24Moved from Aug 22, 2026

Follow CAPR's trial news. Pro members can get an alert when Capricor Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when CAPR files news on its trialsFree for 24 hours. No account needed.

Pipeline and cash

What's next for CAPR, and how long its cash lasts

From Capricor Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Nov 22In 51 days“– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –”FDA decision date · 8-K, Aug 24

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

2 more trials, 38 filings, for Pro members.

Cash runway

The company says its cash lasts into Q4 2027 (8-K, May 12).

That is the company's own estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Sep 10, 2025)
At-the-market share sales program (S-3, filed Sep 10, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CFO Anthony Bergmann sold 24,100 shares on Jun 25. 9 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Linda Marban buys or sells

For Pro members: every trade, and Linda Marban’s 3 filings and quotes.

Get an optional alert before CAPR's FDA date

Free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $122MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $130MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $486MDrug not namedUnder FDA review

8 more FDA dates and 107 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why CAPR scores -3

PoorChoppy, 2 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

+2Chart checks 2 of 14 firing right now, one point each
−2Long-term trend below a falling 200-⁠day average, down over two years

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Run-up, Size, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on CAPR and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 1:06 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Tue Nov 10, after the close

After its last 4 reports it closed +14.2% on average, higher 2 of 4 times.

What would turn CAPR's score around: 6 things, for Pro members

Alert me when CAPR's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A Pro member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest — A card on the scanner, shown on AMD

A Pro member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart — A stock page

The scanner a Pro member sees: every stock as a card with its Quality Score, rank, and chart checks bar, and the watchlist — The scanner

The 14 checks

CAPR has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on CAPR, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1449.4
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 34 sessions ago.
50-day average$8.20
The price is 9.0% above it.
200-day average$22.88
The price is 60.9% below it. The 50-day is below the 200-day, since Aug 3.
ADX 1412.8
Under 25, with +DI above -DI.
Support$8.18
Swing low from Sep 10, 8.5% below the price.
Resistance$9.79
Swing high from Sep 17, 9.5% above the price.
Bollinger Bands (20, 2)Inside
The bands run from $8.11 to $9.59.
Volume1.0x
Against its 20-day average, for the time of day.

Its industry

How CAPR ranks in Biotech

CAPR is #182 of 276 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2ABCLAbCellera Biologics6/1416
3OABIOmniAb9/1415
BMRNBioMarin PharmaceuticalsOpen for its score
BNTXBioNTechOpen for its score
CATXPerspective TherapeuticsOpen for its score
CGONCG OncologyOpen for its score
182CAPRCapricor Therapeutics2/14-3

When does CAPR report earnings, and what happens after?

Expected to report Tue Nov 10, after the close (in 39 days). Not yet confirmed by the company.

+11.5%-8.7%-3.8%+58.0%

Nov 10Mar 12May 12Aug 13

Reported	When	Gap	Reaction	5 sessions
Aug 13, 2026After close	After close	+82.0%	+58.0%	+62.4%
May 12, 2026After close	After close	-2.7%	-3.8%	-14.6%
Mar 12, 2026After close	After close	-1.3%	-8.7%	-6.7%
Nov 10, 2025After close	After close	+5.9%	+11.5%	+2.3%

The gap is the next open against the close before the report; the reaction is where that session closed. CAPR closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Filings

Who is trading CAPR

CAPR insider trades

2 insiders sold $1.5M across 6 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellKaren Krasney$732KEVP, General Counselat $30.38 on Jun 25, filed Jun 29

SellKaren KrasneyEVP, General Counsel$732Kat $30.38 on Jun 25, filed Jun 29

All 6 insider filings on CAPR from the last six months, for Pro members.Get in free →

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

The company

About Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

231 employeesSan Diego, CAcapricor.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of CAPR's score, with the points and the reason
All 14 checks on CAPR and on all 2,958 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on CAPR

BreakawayJun 29Karen Krasney sold CAPR$732K at $30.38, filed Jun 29

What a filing on CAPR would have sent. Alerts are optional.

See all 14 checks on CAPRFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.